Ruiz-Pardo J, Ríos-Zambudio A, Rodríguez-González JM, Paredes-Quiles M, Soriano-Giménez V, Oviedo-Ramírez MI, Hernández-Martínez AM, Parrilla-Paricio P. Results of treatment of papillary thyroid microcarcinoma adapted to risk of recurrence.
CIR CIR 2020;
88:576-583. [PMID:
33064693 DOI:
10.24875/ciru.20001560]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Background
The incidence of papillary thyroid microcarcinoma (PTMC) is increasing.
Objective
To analyze the long-term prognosis of PTMC.
Method
Study population: patients with a histopathological diagnosis of PTMC (size ≤ 1 cm) treated according to the risk of recurrence of the Latin American Thyroid Society. Inclusion criteria: minimum follow-up of 2 years, availability of histopathological samples, and treatment compliance. Exclusion criteria: previous thyroid surgery, other synchronous malignancies or ectopic location of the PTMC. Study variables: persistences, recurrences and mortality.
Results
Based on the risk of recurrence, PTMC has very low risk in 65.2% (n = 105), low risk in 17.4% (n = 28) and high risk in 17.4% (n = 28). In high risk patients, total thyroidectomy was performed in all cases, cervical lymphadenectomy in 57,1% (n = 16) and metabolic therapy with I131 in all cases. During a mean follow-up of 119,8 ± 65 months, 0.6% (n = 1) of recurrences took place. Risk factors associated to recurrence were not identified. No patient died due to MCPT.
Conclusions
PTMC treated based on its risk of recurrence has a good long-term prognosis, without persistences, with a low number of recurrences and absence of disease-associated mortality.
Collapse